cholesterolImage Credit source: Getty Images
In today’s time, many health related problems are increasing due to unhealthy diet and sedentary lifestyle. Which also includes increase in bad cholesterol in the body. There are two types of these. Due to which health can be harmed. Due to this, weight may increase. Apart from this, it can accumulate in the arteries, which affects blood flow and increases the risk of heart related problems. Therefore, it is very important to reduce the increased bad cholesterol in the body. For which, along with medicines, doctors advise to do exercise, right lifestyle and healthy diet.
In some cases, even after this, it becomes difficult to reduce the increasing bad cholesterol in the body. In such a situation, a new medicine may come as a hope for those people. Whose name is Enlicitide. It is being said that it can help in reducing cholesterol by 60 percent. But research is still going on. This new pill blocks a protein called PCSK9 present in the liver and this can reduce the amount of bad cholesterol rapidly.
cholesterol reducing drug
The results of Phase 3 trial of this drug are showing that people who took Analyte along with their regular cholesterol-lowering statin drug, after about 24 weeks, there was a reduction of up to 60 percent in the level of bad cholesterol in their body. A total of 2,912 adults, whose age was approximately 63 years, were included in this Phase 3 clinical trial, this study took place between August 2023 and July 2025. All the participants had high levels of bad cholesterol in their bodies and were already taking lipid-lowering treatments such as statins. About 97% of the people were taking statins, and 26% were taking other cholesterol-lowering drugs. After this, while continuing the old treatment, some participants were given one tablet of Analyte daily and some were given placebo.
Their results were seen after 24 weeks. In those who took Analyte along with statins, there was a reduction of about 60 percent in LDL i.e. bad cholesterol. It was also observed that this medicine is not only reducing bad cholesterol but is also showing effect on many other risk factors related to cholesterol. At the same time, there was no improvement in those who took only placebo.
Research is still going on
Further study is needed to know whether this drug will reduce major cardiovascular problems in the long term. Also, further study is needed to find out the rare side-effects that may occur after long-term use. The company that manufactures the drug, Merck, is now preparing to get approval for this drug from the FDA (American drug regulator). If approved, this will be the first pill that can manage cholesterol more effectively in combination with statins. These results have not yet been published in any scientific journal, but have been presented in the Scientific Season of the American Heart Association (AHA). These results have not yet been published publicly in the scientific paper, so they should be viewed with caution. Research on this is still going on.